Department of Neurology, Østfold Hospital Trust, Grålum, Norway.
Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Eur Stroke J. 2023 Mar;8(1):148-156. doi: 10.1177/23969873221123122. Epub 2022 Oct 20.
Secondary stroke prevention depends on proper identification of the underlying etiology and initiation of optimal treatment after the index event. The aim of the NOR-FIB study was to detect and quantify underlying atrial fibrillation (AF) in patients with cryptogenic stroke (CS) or transient ischaemic attack (TIA) using insertable cardiac monitor (ICM), to optimise secondary prevention, and to test the feasibility of ICM usage for stroke physicians.
Prospective observational international multicenter real-life study of CS and TIA patients monitored for 12 months with ICM (Reveal LINQ) for AF detection.
ICM insertion was performed in 91.5% by stroke physicians, within median 9 days after index event. Paroxysmal AF was diagnosed in 74 out of 259 patients (28.6%), detected early after ICM insertion (mean 48 ± 52 days) in 86.5% of patients. AF patients were older (72.6 vs 62.2; < 0.001), had higher pre-stroke CHA₂DS₂-VASc score (median 3 vs 2; < 0.001) and admission NIHSS (median 2 vs 1; = 0.001); and more often hypertension ( = 0.045) and dyslipidaemia ( = 0.005) than non-AF patients. The arrhythmia was recurrent in 91.9% and asymptomatic in 93.2%. At 12-month follow-up anticoagulants usage was 97.3%.
ICM was an effective tool for diagnosing underlying AF, capturing AF in 29% of the CS and TIA patients. AF was asymptomatic in most cases and would mainly have gone undiagnosed without ICM. The insertion and use of ICM was feasible for stroke physicians in stroke units.
二级卒中预防取决于对指数事件后潜在病因的正确识别和最佳治疗的启动。NOR-FIB 研究的目的是使用可植入心脏监测仪(ICM)检测和量化隐源性卒中(CS)或短暂性脑缺血发作(TIA)患者的潜在心房颤动(AF),以优化二级预防,并测试 ICM 在卒中医生中的使用可行性。
前瞻性观察性国际多中心真实世界研究,对 CS 和 TIA 患者进行 12 个月的 ICM(Reveal LINQ)监测,以检测 AF。
91.5%的患者由卒中医生进行 ICM 插入,中位数时间为指数事件后 9 天。259 例患者中,74 例(28.6%)诊断为阵发性 AF,86.5%的患者在 ICM 插入后早期(平均 48±52 天)检测到 AF。AF 患者年龄较大(72.6 岁比 62.2 岁; <0.001),CHA₂DS₂-VASc 评分较高(中位数 3 分比 2 分; <0.001)和入院 NIHSS 评分(中位数 2 分比 1 分; = 0.001);且更常见高血压( = 0.045)和血脂异常( = 0.005)。心律失常复发率为 91.9%,无症状率为 93.2%。在 12 个月的随访中,抗凝剂使用率为 97.3%。
ICM 是诊断潜在 AF 的有效工具,可在 29%的 CS 和 TIA 患者中检测到 AF。在大多数情况下,AF 是无症状的,如果没有 ICM,它将主要未被诊断。在卒中病房中,卒中医生可以对 ICM 进行插入和使用。